Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 7/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825775 | 0.86 | MAP4K4 (0.40) | MAP4K4IKBKBCHUKMAPK14KDM4C | |
| SCHEMBL6825733 | 0.83 | MAP4K4 (0.46) | MAP4K4IKBKBCHUKMAPK14KDM4C | |
| SCHEMBL6825658 | 0.82 | CYP2A6 (0.43) | — | |
| SCHEMBL6827724 | 0.75 | KDM4E (0.39) | MAP4K4BCHEACHEKDM5BPDGFRB | |
| SCHEMBL6825688 | 0.74 | MAP4K4 (0.37) | MAP4K4PIM1 | |
| SCHEMBL4825593 | 0.71 | ACP1 (0.57) | BCHEACHEACP1 | |
| SCHEMBL4025078 | 0.69 | RXFP1 (0.42) | MAP4K4ACP1 | |
| SCHEMBL6822491 | 0.69 | MAPK1 (0.41) | DPP4 | |
| SCHEMBL4823424 | 0.69 | MAP4K4 (0.43) | MAP4K4ACHEACP1 | |
| SCHEMBL4031738 | 0.69 | DHODH (0.45) | MAP4K4ACP1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214833-A1 | Tricyclic heteroaromatic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| WO-2004089950-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-21 | — | — | WO | claimed |
| US-20040214833-A1 | Tricyclic heteroaromatic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| WO-2004089950-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214833-A1 | Tricyclic heteroaromatic compounds | CYP1A1, SULT2A1, CYP1B1 | MAP4K4 3740/4885IKBKB 2214/4885CHUK 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.